RxDoctor Payments Data

Alan Downen, MD

Hospitalist · Wichita, KSNPI 1083052211

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 56.8% of the total. Reporting peaked in 2019 at $77 and has fallen 77.4% since, to $17 in 2024.

$136in general payments, 2019–2025

Across 5 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$77
  • Bard Access Systems, Inc.$23
  • Neurocrine Biosciences, Inc.$17
  • Amgen$14
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4

What the payments were for

  • Food & beverage$136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$136 in reported general payments places this provider in the 80th percentile of 178 hospitalist providers in Kansas.

See all hospitalist providers in Kansas

Medicare billing

Part B allowed, 2024
$422,571
Medicare patients
652
Services billed
4,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban824$84,621
Invega SustennaPaliperidone Palmitate23$82,276
JardianceEmpagliflozin500$54,629
TrulicityDulaglutide35$29,395
XareltoRivaroxaban291$27,697
Atorvastatin Calcium2,337$14,427
RexultiBrexpiprazole72$13,196
JanuviaSitagliptin Phosphate71$11,082
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,952
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,320
MyrbetriqMirabegron80$9,093
Losartan Potassium1,407$8,162
Levothyroxine Sodium1,212$6,977
LinzessLinaclotide12$6,749
Bumetanide734$5,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$77$6,74912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 178 hospitalist providers in Kansas.

Other hospitalist in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →